Compare Quest Diagnostics Inc (DGX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Prospect Capital Corporation — how do they compare? Quest Diagnostics Inc trades at $236.97 (market cap $26.21B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Quest Diagnostics Inc is far larger — about 23× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.
| DGX | PSEC | |
|---|---|---|
Market Cap | $26.21B | $1.14B |
Sector | Health | Financials |
52-Week High | $238.50 | $3.05 |
52-Week Low | $173.49 | $2.11 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
PSEC trades at $2.29, down 1.72% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock carries a low P/B of 0.39 and has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $469.92 million in 2025. Recent news includes a dividend increase announcement and the sale of portfolio company Valley Electric for $328 million.
The outlook is cautious; while the deep discount to book value and consistent dividend payments offer income appeal, significant negative revenue and net income margins, alongside a divided analyst consensus, highlight substantial business and market risks. The primary opportunity lies in a potential valuation recovery if operational performance improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
